Graf Akcie CYAD (Celyad Oncology). Diskuze k akciím CYAD. Aktuální informace CYAD.

Základní informace o společnosti Celyad Oncology (Akcie CYAD)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 68.48M
Hodnota podniku (EV) N/A
Tržby N/A
EBITDA N/A
Zisk -€17.20
Růst v tržbách Q/Q N/A %
Růst v tržbách Y/Y N/A %
P/E (Cena vůči ziskům) N/A
Forward P/E N/A
EV/Sales 11,187.12
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 22,390.67
P/FCF N/A
Price/Book 1.83
Účetní hodnota na akcii 2.42
Hotovost na akcii N/A
FCF vůči ceně -39.97 %
Počet zaměstnanců 83
Tržba na zaměstnance €30.12
Profit margin -344,080.00 %
Operating margin -524,800.00 %
Gross margin 100.00 %
EBIT margin -1,029,600.00 %
EBITDA margin -331,979.27 %
EPS - Zisk na akcii -3.34
EPS - Kvartální růst N/A %
EPS - Očekávaný růst příští rok N/A %
Return on assets -21.04 %
Return on equity -44.91 %
ROIC -33.66 %
ROCE -50.48 %
Dluhy/Equity 1.13
Čistý dluh/EBITDA 3.60
Current ratio 1.67
Quick Ratio 1.53
Volatilita 4.47
Beta 0.35
RSI 58.62
Cílová cena analytiků 23
Známka akcie (dle analytiků) 1.43
Insider ownership 0.00 %
Institutional ownership 7.06 %
Počet akcií 15.494M
Procento shortovaných akcií 0.00 %
Short ratio 13.06 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 2015
Země 0

Finanční výsledky akcie CYAD

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$0.007$3.679$4.001$9.432$0.003$0.194-
Cost Of Goods Sold--$0.582$0.059$7.087$0.153$3.208
Gross Profit$0.007$3.679$3.419$9.373$-7.083$0.041$-3.208
Research And Development Expenses$28.22$27.844$25.893$30.625$6.55$21.089$2.867
SG&A Expenses$10.158$12.267$10.523$10.783$8.028$6.668$3.968
Other Operating Income Or Expenses$6.027$-8.646$-26.769$3.696$-11.286$5.866$-5.856
Operating Expenses$32.351$48.758$63.767$37.771$32.951$22.044$15.899
Operating Income$-32.345$-45.079$-59.766$-28.339$-32.948$-21.85$-15.899
Total Non-Operating Income/Expense$0.268$0.876$-3.98$2.21$0.62$-0.021$-0.501
Pre-Tax Income$-32.077$-44.201$-63.744$-26.129$-32.328$-21.871$-16.4
Income Taxes$-0.009-$-0.001$-0.007---
Income After Taxes$-32.068$-44.201$-63.743$-26.122$-32.328$-21.871$-16.4
Other Income-------
Income From Continuous Operations$-32.068$-44.201$-63.743$-26.122$-32.328$-21.871$-16.4
Income From Discontinued Operations-------
Net Income$-32.068$-44.201$-63.743$-26.122$-32.328$-21.871$-16.4
EBITDA$-30.342$-43.763$-49.589$-26.661$-31.801$-20.693$-14.722
EBIT$-32.345$-45.079$-59.766$-28.339$-32.948$-21.85$-15.899
Basic Shares Outstanding1311109874
Shares Outstanding1311109874
Basic EPS$-2.56$-3.97$-6.62$-2.80$-3.81$-3.24$-4.00
EPS - Earnings Per Share$-2.56$-3.97$-6.62$-2.80$-3.81$-3.24$-4.00
# 2020 2019 2018 2017 2016 2015
Current Ratio3.5935.35834.58077.57149.5235.4411
Long-term Debt / Capital0.06180.01560.01670.010.00380.0103
Debt/Equity Ratio0.09560.02960.03040.01630.00610.0155
Gross Margin10010085.45299.3899-212633.321.2329
Operating Margin-481316.7-1225.361-1493.672-300.4693-989066.5-11258.22
EBIT Margin-481316.7-1225.361-1493.672-300.4693-989066.5-11258.22
EBITDA Margin-451516.7-1189.599-1239.322-282.6821-954633.2-10662.33
Pre-Tax Profit Margin-477333.3-1201.509-1593.107-277.0386-970466.7-11269.18
Net Profit Margin-477200-1201.509-1593.079-276.9682-970466.7-11269.18
Asset Turnover0.00010.0330.04560.0614-0.0033
Inventory Turnover Ratio------
Receiveable Turnover0.00278.487715.19316.27150.00460.0794
Days Sales In Receivables13651043.003224.02458.199679448.344597.5
ROE - Return On Equity-62.7633-67.3257-118.6389-25.9738-26.1175-61.6587
Return On Tangible Equity-303.9492-192.6744-511.4264-57.1311-46.4457-100.2132
ROA - Return On Assets-31.8714-39.6897-72.6496-17.0065-18.2504-37.4136
ROI - Return On Investment-58.8857-66.2777-116.656-25.714-26.0179-61.0207
Book Value Per Share3.66475.49755.444810.798113.29025.0385
Operating Cash Flow Per Share0.3662.329-2.28350.6381-0.14240.018
Free Cash Flow Per Share0.40922.3485-2.19240.5531-0.1323-0.0746